Mercks $620 million Rosetta acquisition in May was great fodder for the industry rumor mill. It seems Mercks CEO Raymond Gilmartin joined Microsofts board just two weeks before the acquisition. Meanwhile, Microsoft has been making noise about pursuing pharma industry business. And a member of Rosettas board is from Vulcan Ventures, the VC outfit run by Microsoft cofounder Paul Allen. What of this tangled web, you ask?
Short reads
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.